Tenpoint Therapeutics has launched with a $70 million Series A financing, which will be used to develop regenerative medicine platforms to replace cells destroyed by inherited and age-related ocular diseases, according to a press release.
“From a patient perspective, we see tremendous opportunity,” Eddy Anglade, MD, CEO of Tenpoint, told Healio. “Our platform can mean the ability to not just stop the progression of disease, but to improve the functioning or replacement of cells that have been lost due to disease.”
The financing round included a new investment from